Jayakumaran Jeyanthan, Hunter Krystal, Roy Satyajeet
Department of Medicine, Cooper University Health Care, Camden, NJ, USA.
Cooper Research Institute, Cooper Medical School of Rowan University, Camden, NJ, USA.
J Clin Med Res. 2020 Jun;12(6):362-368. doi: 10.14740/jocmr4208. Epub 2020 Jun 4.
Bronchial asthma is a common controllable disease that causes a serious economic and social burden. The Global Initiative for Asthma (GINA) was developed to help guide clinicians in appropriate management of asthma. Despite the existence of published guidelines, common practice in many primary care clinics follows usual care based on clinical gestalt. This study aims to determine if there is a statistically significant difference in outcomes between patients receiving guideline-directed therapy when compared to those receiving usual clinician therapy.
A total of 300 patients were included in this study. Among them, 139 patients received guideline-directed medical therapy (GDMT group) and 161 received usual medical therapy (UMT group). Logistic regression models were utilized to determine if there was a significant difference in outcomes for patients comparing number of exacerbations and number of hospitalizations.
More patients in GDMT group suffered from recorded exacerbations in the prior year with 43.9% having one, 3.6% having two, and 0.7% having three, compared to the frequencies of exacerbations in the UMT group (29.2%, 1.9%, and 1.2%, respectively) (P < 0.05). Cumulative number of hospitalizations due to asthma exacerbations in the prior year was also higher in GDMT group compared to the UMT group (one in 5.8% GDMT vs. 3.1% UMT; two in 0.0% GDMT vs. 0.6% UMT) without statistically significant difference (P = 0.349).
Primary care providers' adherence to the 2018 GINA guidelines for asthma treatment did not offer benefit to patient outcomes, such as number of exacerbations or hospitalizations, compared to the usual medical care of bronchial asthma. Patient-tailored care may offer reduction in the rates of exacerbations and hospitalization.
支气管哮喘是一种常见的可控制疾病,会造成严重的经济和社会负担。全球哮喘防治创议(GINA)旨在帮助指导临床医生对哮喘进行恰当管理。尽管已有发布的指南,但许多基层医疗诊所的常规做法仍是基于临床经验进行常规治疗。本研究旨在确定接受指南导向治疗的患者与接受常规临床医生治疗的患者在治疗结果上是否存在统计学上的显著差异。
本研究共纳入300例患者。其中,139例患者接受指南导向药物治疗(GDMT组),161例接受常规药物治疗(UMT组)。使用逻辑回归模型来确定比较急性加重次数和住院次数时患者的治疗结果是否存在显著差异。
GDMT组中更多患者在前一年有急性加重记录,其中43.9%有1次,3.6%有2次,0.7%有3次,而UMT组的急性加重频率分别为29.2%、1.9%和1.2%(P<0.05)。与UMT组相比,GDMT组前一年因哮喘急性加重导致的累计住院次数也更高(GDMT组5.8%有1次住院,UMT组为3.1%;GDMT组0.0%有2次住院,UMT组为0.6%),但无统计学显著差异(P = 0.349)。
与支气管哮喘的常规医疗护理相比,基层医疗服务提供者遵循2018年GINA哮喘治疗指南对患者的治疗结果,如急性加重次数或住院次数,并无益处。针对患者的个性化护理可能会降低急性加重率和住院率。